Search

Your search keyword '"Petra Zürbig"' showing total 3 results
Start Over Author "Petra Zürbig" Publisher elsevier
3 results on '"Petra Zürbig"'

1. Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker

Author

Claudia Pontillo, Zhen-Yu Zhang, Joost P. Schanstra, Lotte Jacobs, Petra Zürbig, Lutgarde Thijs, Adela Ramírez-Torres, Hiddo J.L. Heerspink, Morten Lindhardt, Ronald Klein, Trevor Orchard, Massimo Porta, Rudolf W. Bilous, Nishi Charturvedi, Peter Rossing, Antonia Vlahou, Eva Schepers, Griet Glorieux, William Mullen, Christian Delles, Peter Verhamme, Raymond Vanholder, Jan A. Staessen, Harald Mischak, and Joachim Jankowski

Subjects
biomarker, chronic kidney disease, clinical science, glomerular filtration rate, peptidomics, proteomics, Diseases of the genitourinary system. Urology, RC870-923
Abstract

CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtration rate (eGFR) to

Published
2017
Full Text
View/download PDF

2. A Urinary Fragment of Mucin-1 Subunit α Is a Novel Biomarker Associated With Renal Dysfunction in the General Population

Author

Zhen-Yu Zhang, Susana Ravassa, Martin Pejchinovski, Wen-Yi Yang, Petra Zürbig, Begoña López, Fang-Fei Wei, Lutgarde Thijs, Lotte Jacobs, Arantxa González, Jens-Uwe Voigt, Peter Verhamme, Tatiana Kuznetsova, Javier Díez, Harald Mischak, and Jan A. Staessen

Subjects
collagen, fibrosis, glomerular filtration rate, mucin-1, population science, proteomics, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Sequencing peptides included in the urinary proteome identifies the parent proteins and may reveal mechanisms underlying the pathophysiology of chronic kidney disease. Methods: In 805 randomly recruited Flemish individuals (50.8% women; mean age, 51.1 years), we determined the estimated glomerular filtration rate (eGFR) from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. We categorized eGFR according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative guideline. We analyzed 74 sequenced urinary peptides with a detectable signal in more than 95% of participants. Follow-up measurements of eGFR were available in 597 participants. Results: In multivariable analyses, baseline eGFR decreased (P ≤ 0.022) with urinary fragments of mucin-1 (standardized association size expressed in ml/min/1.73 m2, −4.48), collagen III (−2.84), and fibrinogen (−1.70) and was bi-directionally associated (P ≤ 0.0006) with 2 urinary collagen I fragments (+2.28 and −3.20). The eGFR changes over 5 years (follow-up minus baseline) resulted in consistent estimates (P ≤ 0.025) for mucin-1 (−1.85), collagen (−1.37 to 1.43) and fibrinogen (−1.45) fragments. Relative risk of having or progressing to eGFR

Published
2017
Full Text
View/download PDF

3. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial

Author

Verusca Lecchi, Pamela Surtees, Jessie A. Hermann, Marina Noutsou, Lidmila Francová, Francesca Lo Bue, Silvia Prandini, Annika Durban, Heidrun Wölk, Suzy van Steenderen, Gemma Currie, Rüdiger Göke, Ivan Rychlik, Daniela Cugini, Annette Busmann, Ulrike Wittkop, Svitlana Yakymchuk, John R. Petrie, Slavica S. Stratrova, Stanley M H Yeung, Julia Raad, Antonio Cannata, Ninna Hahn Tougaard, Robbie Wilson, Barbara Neuhaus, Joachim Beige, Olivera Stojceva-Taneva, Harald Mischak, Tine W. Hansen, Giulia Gherardi, Caroline Boukens-de Graaf, Renata Amanaki, Francesco Nones, Anneke K. De Bruin, Aneliya Parvanova, Elizabeth Douglas, Carolina Aparicio, Gerjan Navis, Tereza Havrdova, Alberto Ortiz, Maria Dolores Sanchez-Niño, Simone Theilade, Ferrina Clerc-de Jong, Signe Abitz Winther, Adrian M. Ramos, Regina Ax-Smolarski, Ingo Dimos, Christina M. Gant, Peter Girman, Friedrich W. Petry, Peter Rossing, Bruno Lapauw, Katarina Adamova, Rikke J. Stefansen, Michael Prigge, Mie K. Eickhoff, Petra Zürbig, Viktor Rotbain Curovic, Davide Villa, Goce Spasovski, Marian Nannings, Adriaan Kooy, Joanne Flynn, Therese Frost Lerche, Veit Zieglschmid, Flavio Gaspari, Gjulsen Selim, Marijn M. Speeckaert, Jens C. Laursen, Elsie de Man, Signe Rosenlund, Christian Delles, Giel Nijpels, Katriona Brooksbank, Alessandro Villa, Ilian Iliev, Morten Lindhardt, Maria A. Campbell, Lone Jelstrup, Gozewijn D. Laverman, Matias Trillini, Ulrike Schmidt, Kristin Kreutzmann, Silke Zimmermann, Ceyda Kilic, Tina R. Juhl, Silvia Ferrari, Nadia Stucchi, Beatriz Fernandez-Fernandez, Christian Stevns Hansen, Femke Rutters, Brenda Wierbos, Sabien Inion, Maria Lajer, Justyna Siwy, Jannet Entius, Sascha Pilemann-Lyberg, Lene Aabo, Heiko von der Leyen, Elina Eldeik, Tatjana Gjorgovski, Marie Frimodt-Møller, Isabelle Dewettinck, Maja L.D. Halkjær, Joline W.J. Beulens, Šárka Albrechtová, Stephan J. L. Bakker, Hiddo J.L. Heerspink, Brit Rädisch, Clotilde Vázquez, Ilse J. M. Hagedoorn, Dorthe Riis, Bernt Johan von Scholten, Andreas L. Birkenfeld, Kelly Rokegem, Ana Belen Sanz, Frederik Persson, Eva Bollweber, Anika Hävemeier, Frank Huvers, Petra Schutten-Westerneng, Piero Ruggenenti, Sharon Kean, Maria Á. Gonzalo, Anne G. Lundgaard, Marco Schiemann, Emilie H. Zobel, Nete Tofte, Joe Galloway, Daniela Melacini, Jinny Sanchez-Rodriguez, Groningen Institute for Organ Transplantation (GIOT), Lifestyle Medicine (LM), Groningen Kidney Center (GKC), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Value, Affordability and Sustainability (VALUE), APH - Health Behaviors & Chronic Diseases, General practice, Epidemiology and Data Science, APH - Aging & Later Life, and ACS - Diabetes & metabolism

Subjects
Adult, Male, Proteomics, medicine.medical_specialty, ALBUMINURIA, NEPHROPATHY, Endocrinology, Diabetes and Metabolism, Population, Placebo-controlled study, 030209 endocrinology & metabolism, Spironolactone, DIAGNOSIS, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Randomized controlled trial, law, Internal medicine, Internal Medicine, Clinical endpoint, media_common.cataloged_instance, Medicine, Humans, Diabetic Nephropathies, 030212 general & internal medicine, Prospective Studies, European union, Prospective cohort study, education, media_common, Aged, Mineralocorticoid Receptor Antagonists, education.field_of_study, business.industry, MICROALBUMINURIA, Middle Aged, medicine.disease, Editorial Commentary, Early Diagnosis, Treatment Outcome, Diabetes Mellitus, Type 2, Cohort, Disease Progression, Microalbuminuria, Female, business, Glomerular Filtration Rate
Abstract

Background: \ud Microalbuminuria is an early sign of kidney disease in people with diabetes and indicates increased risk of cardiovascular disease. We tested whether a urinary proteomic risk classifier (CKD273) score was associated with development of microalbuminuria and whether progression to microalbuminuria could be prevented with the mineralocorticoid receptor antagonist spironolactone.\ud \ud Methods: \ud In this multicentre, prospective, observational study with embedded randomised controlled trial (PRIORITY), we recruited people with type 2 diabetes, normal urinary albumin excretion, and preserved renal function from 15 specialist centres in ten European countries. All participants (observational cohort) were tested with the CKD273 classifier and classified as high risk (CKD273 classifier score >0·154) or low risk (≤0·154). Participants who were classified as high risk were entered into a randomised controlled trial and randomly assigned (1:1), by use of an interactive web-response system, to receive spironolactone 25 mg once daily or matched placebo (trial cohort). The primary endpoint was development of confirmed microalbuminuria in all individuals with available data (observational cohort). Secondary endpoints included reduction in incidence of microalbuminuria with spironolactone (trial cohort, intention-to-treat population) and association between CKD273 risk score and measures of impaired renal function based on estimated glomerular filtration rate (eGFR; observational cohort). Adverse events (particularly gynaecomastia and hyperkalaemia) and serious adverse events were recorded for the intention-to-treat population (trial cohort). This study is registered with the EU Clinical Trials Register (EudraCT 20120-004523-4) and ClinicalTrials.gov (NCT02040441) and is completed.\ud \ud Findings: \ud Between March 25, 2014, and Sept 30, 2018, we enrolled and followed-up 1775 participants (observational cohort), 1559 (88%) of 1775 participants had a low-risk urinary proteomic pattern and 216 (12%) had a high-risk pattern, of whom 209 were included in the trial cohort and assigned to spironolactone (n=102) or placebo (n=107). The overall median follow-up time was 2·51 years (IQR 2·0–3·0). Progression to microalbuminuria was seen in 61 (28%) of 216 high-risk participants and 139 (9%) of 1559 low-risk participants (hazard ratio [HR] 2·48, 95% CI 1·80–3·42; p

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results